TAMs contribute to tumor progression by providing a barrier against anti-tumor T-cell immunity and help to predict the prognosis of DLBCL patients.21,38 To our knowledge, this is the first report on the impact of CREBBP and EP300 mutation on TAMs, suggesting an alternative mechanism of epigenetic alterations on tumor microenvironment in DLBCL. Here, EP300 is linked to diffuse large B-cell lymphoma.